Latest "Ambrx Inc." News Stories

04:58 EDT 19th March 2018 | BioPortfolio

Here are the most relevant search results for "Ambrx Inc." found in our extensive news archives from over 250 global news sources.

More Information about Ambrx Inc. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Ambrx Inc. for you to read. Along with our medical data and news we also list Ambrx Inc. Clinical Trials, which are updated daily. BioPortfolio also has a large database of Ambrx Inc. Companies for you to search.

Showing "Ambrx" News Articles, all 11

Tuesday 16th January 2018

Sanifit appoints CFO

Cris Calsada joins the biopharma from Ambrx

Friday 5th January 2018

Ambrx gets Chinese rights to Tracon's carotuximab

Tuesday 2nd January 2018

Ambrx gets Chinese rights to Tracon's endoglin antibody TRC105

Tracon Pharmaceuticals Inc. granted Ambrx Inc. exclusive rights to develop and sell the endoglin antibody TRC105 (carotuximab...

Sunday 24th December 2017

Week in Review: Nearly $2 Billion Late-December Week for China Pharma Deals

Deals and Financings  Nanjing Legend Biotech received a very large $350 million upfront payment from Janssen Biotech to partner Legend's impressively effective CAR-T candidate; Crown Bioscience, a CRO with facilities in China and elsewhere, will be acquired for $400 million by Japan's JSR, double its previous valuation; JHL Biotech is planning a voluntary delisting from the Taiwan stock exch...

Friday 22nd December 2017

Ambrx Enters $143.5 Million China Deal for Liver Cancer Treatment

Ambrx announced a $143.5 million agreement to in-license China rights for a liver cancer treatment with an anti-angiogenesis mechanism, developed by Tracon Pharma of San Diego. Two years ago, Ambrx, a San Diego-Shanghai antibody-conjugate biotech company, was acquired by Fosun Pharma (SHA: 600196; HK: 02196) and WuXi PharmaTech plus two China equity investors. The new agreement gives Ambrx rights ...

Thursday 21st December 2017

Ambrx and TRACON Pharmaceuticals Announce Development and Commercialization Agreement for ...

The transaction grants Ambrx the exclusive rights to develop and commercialize TRC105 in all indications (excluding ophthalmology, which are held by Santen Pharmaceutical Co., Ltd.) Read more...

TRACON and Ambrx Enter Development Agreement

The partnership resolves around the commercialization and development of TRC105 (carotuximab) in China

Wednesday 20th December 2017

TRACON Pharmaceuticals and Ambrx Announce Development and Commercialization Agreement for TRC105 in China

Initial Focus in China on Angiosarcoma and Hepatocellular Carcinoma Total Value of Deal up to $143.5 Million for TRACON, Including

TRACON Pharma, Ambrx Ink Deal Up to $143.5M for TRC105

TRACON will receive an upfront payment of $3M, and is eligible to receive development and regulatory milestones of up to $10.5M, and commercial sales milestones of up to $130M.

Tuesday 19th December 2017

Ambrx Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 14112017] Prices from USD $250

SummaryAmbrx Inc Ambrx is a biopharmaceutical company which focuses on the discovery and development of proteinbased medicines by using its expanded genetic code. The company's pipeline product candidate's portfolio includes ARX618 FGF21, PSMA ADC, CD70 ADC and AntiCD3 X Folate. It develops pipeline candidates for various therapeutic indications such as diabetes, oncology and heart failure. Ambrx ...

Monday 4th December 2017

TP Therapeutics Appoints Sheila K. Gujrathi, MD to Board of Directors and as a Strategic Advisor

TP Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company focusing on addressing oncology drug resistance, announced the appointment of Sheila K. Gujrathi MD to the Company’s Board of Directors and as a strategic advisor. “The Board and I are extremely delighted to have Dr. Sheila Gujrathi join us as director and strate...

Quick Search


News Quicklinks